Prolongation of liver xenograft survival by adenovirus vector-mediated CTLA-4Ig gene transfer.

Cytotoxic T lymphocyte-associated antigen-4/immunoglobulin fusion products (CTLA-4Ig), a structural homologue of CD28, has been shown to inhibit cellular and humoral immune responses. In this study, we investigated the efficacy of an adenovirus vector containing the CTLA-4Ig gene (AdCTLA-4Ig) on recipient survival after hamster-to-rat liver xenografting. AdCTLA-4Ig was administrated intravenously immediately after grafting. Gene expression was achieved a maximum of 7 days after vector injection and continued for more than 4 weeks. The proportion of CD25[sup +] T-cells in recipient lymph nodes was significantly reduced 7 days after administration of AdCTLA-4Ig, compared to a group given an adenoviral vector containing LacZ gene (AdLacZ) or to an untreated control group. AdCTLA-4Ig markedly reduced CD2[sup +] T-cell infiltration into the graft and significantly prolonged recipient survival time (9.2±4.12 days), compared to the untreated group (5.4±0.78 days) (P<0.001) and the AdLacZ-treated group (5.2±0.28 days) (P < 0.001). These results indicate that a blockade of T-cell co-stimulation by AdCTLA4Ig inhibited T-cell activation and attenuated CD2[sup +] T-cell infiltration into the xenograft, resulting in significant prolongation of recipient survival time. Thus, AdCTLA-4Ig therapy may provide a novel approach to immune regulation. [ABSTRACT FROM AUTHOR]